http://www.novartis.com/newsroom/feature-stories/feature-stories-2011.shtml Get the latest on Novartis through recent headlines, feature stories and videos. en http://www.bostonglobe.com/opinion/2012/05/11/defining-moment-for-made-usa/KOLkqfrHeebGGBtmjzxKMK/story.html "I believe the US manufacturing sector is at a critical point in history. Some people tend to focus on the negative headlines, like a recent study that found 55 percent of Americans think manufacturing is becoming weak and unstable. And while it’s true that around 1,300 manufacturing jobs were lost every day over the last 12 years, I see several opportunities for a shift that is starting to emerge". Fri, 11 May 2012 16:30:00 +0100 http://www.youtube.com/watch?v=ruIJCvBjcPo As a healthcare company, Novartis recognizes that employees are an integral part of the company's success and a healthy workforce underpins business growth. The "Be Healthy" initiative, first introduced in 2011, has expanded to include all Novartis associates across 140 countries. Wed, 09 May 2012 11:30:00 +0100 http://bowencraggs.com/ftindex Bowen Craggs ranks Novartis No.8 in its 6th annual index of corporate web effectiveness, making it the second healthcare company on the list. Mon, 07 May 2012 17:30:00 +0100 http://interbrandonline.com/bestswissbrands/ Novartis named #3 Most Valuable Swiss Brand 2012 by Interbrand/Bilanz with a brand value of CHF 6.8 billion. Fri, 04 May 2012 10:30:00 +0100 http://novcont05d.na.novartis.net/newsroom/media-releases/en/2012/1605231.shtml Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD 1.525 billion in an all-cash transaction. Thu, 03 May 2012 10:30:00 +0100 http://novcont05d.na.novartis.net/newsroom/media-releases/en/2012/1605231.shtml Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges Tue, 24 Apr 2012 10:30:00 +0100 http://www.youtube.com/watch?v=16plJGNvJX8 Leo and Kya are very good friends. Kya is from Africa, and one day, she was telling Leo about malaria in Africa ... Help raise awareness, educate your children and join the fight against malaria! Thu, 19 Apr 2012 11:00:00 +0100 http://www.youtube.com/watch?v=ZzaNQG6CVeg&list=UUSg28bDoEVjVegY4-htQM7A&feature=plcp What if questions have always driven human progress. With today's health challenges, medical progress is more important than ever. Fri, 13 Apr 2012 13:00:00 +0100 http://www.mmm-online.com/orphan-drugs-small-is-the-new-big/article/233445/ A target of 300 endocrinologists seems pretty specific. And small. After all, health headlines often focus on broad issues, like the 78 million obese adults or the 26 million Americans with diabetes. Wed, 04 Apr 2012 18:45:00 +0100 http://www.novartis.com/newsroom/media-releases/en/2012/1597980.shtml Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature and released in advance online today[1], may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research. Wed, 28 Mar 2012 18:00:00 +0100 http://brandirectory.com/league_tables/table/global-500-2012 Novartis ranked as one of the “Global 500 most valuable brands” and one of the top brands in the pharmaceutical/healthcare sector. Mon, 19 Mar 2012 17:00:00 +0100 http://www.diversityjournal.com/7695-joseph-jimenez-novartis-ag/ Mr. Jimenez was recognized for his commitment and engagement in Novartis Diversity & Inclusion initiatives. Wed, 14 Mar 2012 18:00:00 +0100 http://money.cnn.com/magazines/fortune/most-admired/2012/industries/43.html Novartis again ranked top pharmaceutical company in Fortune’s World’s Most Admired Companies 2012 Fri, 02 Mar 2012 18:45:00 +0100 http://www.novartis.com/newsroom/feature-stories/2012/02/novartis-works-for-patients-with-rare-diseases.shtml From pioneering Novartis medicines used by patients worldwide to treat rare forms of cancer to potential medical breakthroughs now undergoing clinical testing, our commitment to rare diseases has never been stronger. Underscoring that commitment, Novartis headquarters in Basel, Switzerland, will host the RE(ACT) Congress, the first international congress on research of rare and orphan diseases, from February 29 to March 2. Fri, 24 Feb 2012 18:45:00 +0100 http://www.youtube.com/watch?v=9lXsHTkw5Dc&feature=channel_video_title One child dies from malaria every minute, so a child-friendly medicine against the disease is critical. Novartis and MMV began working together in 2003 to develop the first pediatric formulation for an artemisinin combination therapy (ACT) against malaria. Wed, 22 Feb 2012 17:00:00 +0100 http://www.mmv.org/newsroom/press-releases/delivery-child-friendly-antimalarial-hits-100-million-mark In 2009, Novartis and MMV launched the first child friendly artemisinin-combination therapy (ACT), meeting the calls from UNICEF and the WHO for age-appropriate medicines. Three years after launch, deliveries of this child-friendly antimalarial hit the 100 million mark. Wed, 22 Feb 2012 14:00:00 +0100 http://www.youtube.com/watch?v=S-QAIB4j5jo&feature=channel_video_title Novartis CEO Joseph Jimenez explains the company's commitment to fighting leprosy and why we need continued focus to eliminate the disease. Tue, 14 Feb 2012 16:00:00 +0100 http://www.prnewswire.com/news-releases/university-teams-tap-mobile-phones-and-social-networks-to-fight-non-communicable-diseases-139044199.html New solutions developed by university teams could help manage the growing global problem of noncommunicable diseases (NCDs) such as asthma, diabetes, stroke and cancer. These innovations were part of the NCD Challenge, sponsored by IBM and Novartis. Fri, 10 Feb 2012 12:00:00 +0100 http://www.novartis.com/newsroom/feature-stories/2012/01/fight-to-help-end-leprosy-2012.shtml Novartis announced today that it will extend its collaboration with the World Health Organization and others to end leprosy. Mon, 30 Jan 2012 12:00:00 +0100 http://www.novartis.com/newsroom/media-releases/en/2012/1579903.shtml Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011. Wed, 25 Jan 2012 07:00:00 +0100 http://www.youtube.com/watch?v=tqgOCH2G1ds&feature=email "SMS for Life" uses SMS and web based technology to expand access to medicines in the most remote areas of the world. After Tanzania and Ghana, "SMS for Life" is being implemented in Kenya and beyond antimalarials, RDTs, bed nets, antibiotics or patient surveillance data can now also be monitored. Tue, 17 Jan 2012 15:30:00 +0100 http://www.youtube.com/watch?v=-Z5lOrmfjKg The Becoming Christopher video trailer tells the fictional story of Christopher Morgan, a 22-year-old fictional character with cystic fibrosis, on his journey to adulthood. Mon, 16 Jan 2012 11:00:00 +0100 http://www.youtube.com/watch?v=ZtgClWUd_9A&feature=channel_video_title Malaria remains a complex and multi-faceted problem in sub-Saharan Africa. Professor Rodriguez, Harvard University, Professor Coll-Seck, Exec. Dir. Roll Back Malaria, and Agnes Akoth, head nurse, Kombewa Clinic in Kenya, look more closely at the impact of malaria in Africa, and examine the journey Novartis undertook to apply innovation and make global access possible for patients of all backgrounds, in all locations. Thu, 22 Dec 2011 09:00:00 +0100 http://www.youtube.com/watch?v=NcAZ2RTEOSY&feature=channel_video_title In December, 2011 in Basel, the 16th annual symposium of the Novartis Foundation for Sustainable Development (NFSD) discussed the potential of Information and Communication Technologies (ICT) for democratization and development. Mon, 19 Dec 2011 18:00:00 +0100 http://www.novartisfoundation.org/page/content/index.asp?nlYear=&MenuID=324&ID=2214&ConID=2214&View=&Item=73.1.2 The rise of new media has sparked a real knowledge revolution – this is the conclusion of the annual symposium of the Novartis Foundation for Sustainable Development (NFSD), attended by around 500 participants on 2 December 2011, on the topic of "New media: drivers of democratization and development?" Mon, 19 Dec 2011 15:30:00 +0100 http://www.novartis.com/newsroom/media-releases/en/2011/1568363.shtml Experts analyze how e-health applications improve access to quality healthcare and help contribute to achieving the health-related Millennium Development Goals. The symposium discusses the role of social media platforms in the Arab Spring and the impact of mobile phone penetration into the African continent. The annual Novartis Foundation symposium provides an important platform for dialogue on development policy issues. Fri, 02 Dec 2011 15:00:00 +0100 http://www.youtube.com/watch?v=Kk1XOucuiu4&feature=channel_video_title See how scientists at the Novartis Institutes for BioMedical Research, have embraced a new way of thinking about disease that looks at the role of molecular pathways. Wed, 30 Nov 2011 12:00:00 +0100 http://www.novartis.com/newsroom/feature-stories/2011/11/fighting-malaria-2011.shtml Novartis and collaborators discover new class of antimalarial compounds with potential to both prevent and treat malaria infections. Thu, 17 Nov 2011 20:00:00 +0100 http://www.novartis.com/newsroom/feature-stories/2011/11/malaria-initiative-1.shtml In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria - without profit - for use by public health systems in developing countries. Thu, 17 Nov 2011 20:00:00 +0100 http://www.novartis.com/careers/rankings-awards/index.shtml Novartis received three 2011 Scrip Awards: Pharma Company of the Year, Best New Drug and Executive of the Year. Thu, 10 Nov 2011 16:00:00 +0200 http://www.thedailybeast.com/newsweek/features/green-rankings/2011/international.html Novartis ranks no. 34 on the global list of Newsweek’s 2011 “Green Rankings.” For the first time this year, Newsweek expanded its “Green Rankings” to analyze the green score of the 100 biggest companies worldwide. Tue, 8 Nov 2011 18:00:00 +0200 http://www.justmeans.com/top-global-1000-companies/industry/Pharmaceuticals/395 Novartis ranks #6 in the “Sustainable Performance Leaders in Pharmaceuticals” list released by JustMeans. Tue, 8 Nov 2011 17:30:00 +0200 http://money.cnn.com/galleries/2011/news/companies/1111/gallery.top_companies_leaders.fortune/25.html Novartis ranks #25 in Fortune’s 2011 “Global Top Companies for Leaders” list for the quality of its leadership practices. Tue, 8 Nov 2011 15:30:00 +0200 http://www.novartis.com/careers/rankings-awards/index.shtml Novartis is named “Most Admired Pharmaceutical Company” by MedAdNews. Fri, 28 Oct 2011 16:15:00 +0200 http://www.novartis.com/careers/rankings-awards/index.shtml These global awards recognize game-changing innovations that break with conventional ideas or processes, go beyond marginal improvements and have a wide impact in their field. Led by Novartis, in partnership with IBM, Vodafone, the Ministry of Health in Tanzania, and under the umbrella of the Roll Back Malaria Partnership, SMS for Life harnesses everyday technology to improve access to essential malaria medicines in rural areas. Since rolling out nationally across Tanzania in April 2011, the program has expanded to Ghana and Kenya. Tue, 18 Oct 2011 18:00:00 +0200 http://www.eurobrand.cc/en/publication/eurobrand_2011 Novartis was ranked the most valuable healthcare brand in Europe (no. 20) and the third most valuable worldwide (no. 54) in the annual “eurobrand” rankings published by the European Brand Institute, Europe’s leading research institute for intangible assets. Mon, 17 Oct 2011 18:00:00 +0200 http://www.novartis.com/careers/rankings-awards/index.shtml Novartis is named the “Pharmaceutical Company of the Year” by MedAdNews. Fri, 7 Oct 2011 13:00:00 +0200 http://www.youtube.com/watch?v=ceUHRAoUMYs&feature=youtu.be Joseph Jimenez, CEO of Novartis, talks about how Novartis Group Company associates across 32 countries are participating in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011. Mon, 19 Sep 2011 16:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2011/09/be-healthy.shtml Be Healthy aims to help Novartis Group Company associates around the world embrace healthy lifestyles by providing opportunities for them to take control of their personal health and help prevent future health issues. Mon, 19 Sep 2011 07:20:00 +0200 http://www.novartis.com/newsroom/media-releases/en/2011/1547454.shtml Novartis Group Company associates across 32 countries will participate in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011. During the week, Novartis Group sites are offering many opportunities to help associates take control of their personal health. This includes providing information, activities and tips to promote health and help prevent future health issues. Mon, 19 Sep 2011 07:15:00 +0200 http://www.novartis.com/newsroom/media-releases/en/2011/1546023.shtml Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division. The company's diversified healthcare portfolio across high growth segments in healthcare as well as geographic distribution provides Novartis with strength and advantages to benefit from current trends in healthcare as well as protection from macroeconomic effects. Tue, 13 Sep 2011 12:00:00 +0200 http://www.youtube.com/watch?v=IUD5qW7GPok&feature=youtu.be Today's best young talent will soon be changing the world. Novartis International Biotechnology Leadership Camp (BioCamp) offers top university students the opportunity to apply their bright minds to the trends and challenges of the biotechnology and healthcare industry and think like entrepreneurs. This year's BioCamp welcomed 60 participants to Novartis Headquarters in Basel, Switzerland, from August 29 to August 31, 2011. Fri, 2 Sep 2011 10:30:00 +0200 http://novcont05.eu.novartis.net/newsroom/feature-stories/2011/09/biocamp.shtml Future science and business leaders gathered at Novartis as some of the world’s most talented students met and exchanged ideas at the International BioCamp. Thu, 1 Sep 2011 10:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2011/09/biocamp.shtml Today, Novartis opened its eighth annual International Biotechnology Leadership Camp (BioCamp), a three-day seminar bringing biotechnology and business experts together with 60 selected students from leading international universities in 24 countries and territories. This year, Novartis highlighted the growing role of diversity in Group Companies worldwide to drive innovation in all aspects of the company including scientific research and development. Thu, 01 Sep 2011 17:10:00 +0200 http://www.novartis.com/newsroom/media-releases/en/2011/1541763.shtml Future science and business leaders gathered at Novartis as some of the world’s most talented students met and exchanged ideas at the International Biotechnology Leadership Camp (BioCamp). Mon, 29 Aug 2011 07:30:00 +0200 http://www.youtube.com/watch?v=0LHZAo4hYQE&feature=youtu.be Dr. David Ross and Dr. Claire Harrison address the prognosis of myelofibrosis. Thu, 13 Jul 2011 17:40:00 +0200 http://www.youtube.com/watch?v=TN38ZmZLlC0&feature=youtu.be Dr. Alessandro Vannucchi explains how myeloproliferative neoplasms (MPNs) are diagnosed. Thu, 07 Jul 2011 14:30:00 +0200 http://www.youtube.com/watch?v=_x6zCR4GQAc&feature=youtu.be Dr. Claire Harrison explains myeloproliferative neoplasms (MPNs). Thu, 07 Jul 2011 14:30:00 +0200 http://www.novartis.com/newsroom/media-releases/en/2011/1523978.shtml Novartis today held a groundbreaking ceremony to announce the start of construction of a pharmaceutical manufacturing plant in St. Petersburg, Russia. The construction of this facility represents the most significant Novartis investment in Russia to date. This facility will further expand the company's capabilities to produce and deliver both innovative pharmaceuticals and high-quality generics to Russian patients. Thu, 16 Jun 2011 17:30:00 +0200 http://www.youtube.com/watch?v=InFvWF3qv1Q&feature=channel_video_title A woman diagnosed with multiple myeloma that has seriously impacted her bone health, joins a pet therapy program as a way to give back to others. Thu, 16 Jun 2011 13:05:00 +0200 http://www.youtube.com/watch?v=f4jCmi-fkdg&feature=channel_video_title Gastrointestinal Stromal Tumors (GIST) are a rare, life-threatening form of cancer. Listen to four patient stories about living with the disease. Mon, 06 Jun 2011 15:00:00 +0200 http://www.novartis.com/careers/rankings-awards/index.shtml 2011 GBC Business Action on Health Awards 'SMS for Life', a Novartis Malaria Initiative program, ranked #1 in Technology for Health category. Mon, 23 May 2011 17:30:00 +0200 http://www.novartis.com/newsroom/media-releases/en/2011/1517375.shtml Novartis welcomes the decision to endorse the Pandemic Influenza Preparedness Framework (PIP Framework) at the Sixty-fourth World Health Assembly. The PIP Framework sets out the roles and commitments of different stakeholders, including the World Health Organization (WHO) and vaccine manufacturers, in pandemic preparedness. Thu, 19 May 2011 17:30:00 +0200 http://www.novartis.com/newsroom/media-releases/en/2011/1516687.shtml Novartis provides unaudited restated and pro forma consolidated income statement data after the completion of the merger with Alcon, Inc. Wed, 18 May 2011 07:00:00 +0200 http://www.novartis.com/careers/rankings-awards/index.shtml Novartis ranks #6 among large companies for The Scientist Best Places to Work in Industry 2011. Thu, 05 May 2011 11:35:00 +0200 http://www.youtube.com/user/COMOmeningitis Animal research is an important part of the research process when developing new treatments and medicines for patients. No one likes the idea, but as science has not evolved enough to make animal research unnecessary -- for now, this is how we make sure medicines are safe. Tue, 03 May 2011 16:20:00 +0200 http://www.novartis.com/newsroom/feature-stories/2011/04/malaria-initiative-1.shtml In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria – without profit - for use by public health systems in developing countries. Fri, 22 Apr 2011 10:00:00 +0200 http://www.youtube.com/watch?v=rvPNz-JMiHI&feature=channel_video_title Two African mothers struggle to find treatment for their daughters who are battling Malaria. Learn about the severity of the endemic and the complexity surrounding Malaria treatment and diagnosis in Africa. Wed, 20 Apr 2011 10:00:00 +0200 http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Contributions from all businesses led to a good start in 2011, as we achieved 14% growth in the first quarter. We maintained our innovation momentum with new approvals for our multiple sclerosis treatment Gilenya and our eye care treatment Lucentis in the EU. Additionally, promising results of numerous clinical trials, including a Phase III study involving JAK inhibitor INC424, again showed the success of our novel approach to R&D. In April, we completed our merger with Alcon, the leading eye care business in the world, creating the second-largest business in the Novartis portfolio." Tue, 19 Apr 2011 07:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2011/04/stronger-together-1.shtml Together, Novartis and Alcon will hold competitive positions in highly complementary product areas and create an even stronger global leader in the dynamic eye care sector. Fri, 08 Apr 2011 17:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2011/04/ceo-joseph-jimenez-discusses-alcon-merger.shtml We have a great opportunity to redefine and shape the eye care industry, with the ultimate goal of preventing blindness and treating diseases and disorders of the eye. Fri, 08 Apr 2011 17:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2011/04/kevin-buehler-discusses-merger-with-novartis.shtml Completion of the merger with Novartis strengthens Alcon's position as the global leader in eye care and increases the breadth of our eye care portfolio. Fri, 08 Apr 2011 17:00:00 +0200 http://www.novartis.com/careers/biocamp/index.shtml International BioCamp application process for students has begun. Apply today and get qualified for nomination to attend the 3 day event. Fri, 01 Apr 2011 17:00:00 +0200 http://www.youtube.com/watch?v=Yy_rlXoonUU&feature=channel_video_title VetDogs: enriching life for disabled veterans. Watch the video on YouTube Fri, 25 Mar 2011 17:00:00 +0100 http://www.novartis.com/newsroom/media-releases/en/2011/1497585.shtml Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquakevictims Thu, 17 Mar 2011 17:00:00 +0100 http://www.youtube.com/watch?v=1Al4EGC6Zd4&feature=channel_video_title Diagnosing a rare autoinflammatory disease: CAPS. Watch the video on YouTube Tue, 15 Mar 2011 17:00:00 +0100 http://www.novartis.com/newsroom/feature-stories/2010/10/leprosy.shtml Novartis and the World Health Organization (WHO) announced October 11 that they will extend their collaboration to end leprosy. Mon, 11 Oct 2010 19:55:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/08/neglected-diseases.shtml Novartis is pioneering medicines for neglected diseases, with institutes focusing solely on diseases for which research was virtually non-existent. Thu, 05 Aug 2010 21:15:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/07/funding-future-research.shtml Novartis is leading industry efforts to fill a multi-billion-dollar gap in neglected disease R&D funding. Thu, 05 Aug 2010 21:15:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/06/novartis-citizenship.shtml See Novartis Chairman Daniel Vasella, M.D., discuss the values and principles of the United Nations Global Compact on its 10th anniversary. Wed, 23 Jun 2010 14:45:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/06/living-global-compact.shtml In a wide-ranging interview, Klaus Leisinger describes how Novartis embodies the principles of the United Nations Global Compact. Wed, 23 Jun 2010 14:45:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/06/environment-energy.shtml Keith Saveal, Head of Corporate Health, Safety and Environment & Business Continuity, recounts the evolution of the new UN Environmental Stewardship Strategy. Wed, 23 Jun 2010 14:45:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/05/ciba-vision-mobile-app.shtml Eye care professionals are benefiting from an innovative new iPhone® application offering 'anytime, anywhere' access to high-quality educational resources. Fri, 21 May 2010 19:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/04/enhancing-access-antimalarias.shtml On World Malaria Day, April 25, the international community highlights the campaign to provide effective control of this deadly disease. Fri, 23 Apr 2010 09:55:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/04/multiple-sclerosis.shtml People with multiple sclerosis (MS) face devastating uncertainty, not knowing how the disease will progress or disrupt their daily lives. But scientists are developing new diagnostic tools to aid treatment and ease the unpredictability for patients. Thu, 22 Apr 2010 14:07:00 +0200 http://www.novartis.com/newsroom/feature-stories/2010/02/VaxTrak-beyond-vaccine.shtml Novartis Vaccines and Diagnostics (NV&D) has developed a way to help parents, families and vaccine consumers track vaccinations using the iPhone ®. Thu, 18 Feb 2010 19:15:00 +0100 http://www.novartis.com/newsroom/feature-stories/2010/01/new-products-pharmaceutical-portfolio.shtml Just as new medicines are improving the lives of patients fighting serious diseases, success in innovation is rejuvenating the portfolio of Novartis. Recently launched products grew to 16% of net sales for the Pharmaceuticals Division in 2009. Tue, 26 Jan 2010 07:05:00 +0100 http://www.novartis.com/newsroom/feature-stories/2010/01/help-haiti.shtml Novartis joins urgent relief efforts for victims of earthquake in Haiti offering aid in the form of financial support to relief organizations and donations of essential medicines. Fri, 22 Jan 2010 11:15:00 +0100 http://www.novartis.com/newsroom/feature-stories/2010/01/legal-team-navigates-crisis.shtml In times of global financial uncertainty, the Novartis legal team takes an innovative approach – serving as both a protective guardian and a proactive partner to the business. Thu, 14 Jan 2010 21:15:00 +0100 http://www.novartis.com/newsroom/feature-stories/2009/11/biocamp.shtml Today’s best young minds will soon be changing the world. Novartis has created a unique global initiative encouraging top students to apply their intellects in the biotechnology industry – and to think like entrepreneurs. Wed, 25 Nov 2009 17:25:00 +0100 http://www.novartis.com/newsroom/feature-stories/2009/11/good-corporate-governance.shtml A board of directors can restore confidence in the wake of a financial meltdown. On a panel at Yale University, Novartis General Counsel Thomas Werlen helps outline the qualities of a successful board. Wed, 25 Nov 2009 17:25:00 +0100 http://www.novartis.com/newsroom/feature-stories/2009/11/new-treatment-frequent-heartburn.shtml More than 50 million American adults suffer from frequent heartburn. Painful symptoms can disrupt their lives. Now Novartis Consumer Health offers Prevacid®24HR, a new way to treat frequent heartburn over-the-counter. Thu, 12 Nov 2009 08:55:00 +0100 http://www.novartis.com/newsroom/feature-stories/2009/10/new-therapies-multiple-sclerosis.shtml Recent advances in science are enabling new treatments with greater efficacy and more convenient delivery. Novartis is investing significant resources to deliver these treatments to patients with MS. Mon, 19 Oct 2009 13:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2009/10/animal-health-introduces-onsior.shtml An innovative new Novartis product brings fast, effective relief of pain and inflammation for pets. Onsior®, launched in Europe, is the first medication of its class for cats and dogs. The range of dosing options offer convenience for veterinarians and pet owners. Thu, 01 Oct 2009 16:25:00 +0200 http://www.novartis.com/newsroom/feature-stories/2009/09/commitment-fight-against-leprosy.shtml The once-dreaded disease leprosy is on the brink of elimination, but the fight goes on. Novartis commemorates 20 years of helping deliver free care, drugs and rehabilitation in India. Tue, 08 Sep 2009 16:50:00 +0200 http://www.novartis.com/newsroom/feature-stories/2009/07/climate-change.shtml World leaders are focused on climate change and Novartis is, too. Our cutting-edge energy efficiency strategy is a driving long-term success for the environment and for our business. Wed, 22 Jul 2009 11:15:00 +0200 http://www.novartis.com/newsroom/feature-stories/2009/05/life-saving-research-rewarded.shtml Scientists who developed Novartis Coartem® and Glivec® receive 2009 "European Inventor of the Year" awards. Wed, 20 May 2009 14:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2009/04/fight-against-malaria.shtml April 25 is World Malaria Day, an opportunity to reflect on the progress made in finding sustainable solutions for malaria. Fri, 24 Apr 2009 00:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2009/03/revolutionary-collaboration.shtml With declining efficacy and resistance to existing sheep worm treatments on the rise, Novartis Animal Health worked together with sheep farmers and veterinarians to develop an unparalleled new treatment. Tue, 31 Mar 2009 00:00:00 +0200 http://www.novartis.com/newsroom/feature-stories/2009/03/world-tuberculosis-day.shtml As World TB Day on March 24 raises global awareness, Novartis remains a committed partner in the struggle. Thu, 19 Mar 2009 00:00:00 +0100 http://www.novartis.com/newsroom/feature-stories/2009/02/rare-disease-day.shtml The challenges of developing products in rare diseases are many - but no obstacle for Novartis Development teams. Fri, 27 Feb 2009 00:00:00 +0100 http://www.novartis.com/newsroom/feature-stories/2009/02/healthcare-emerging-markets.shtml Novartis is working to expand its offering in emerging markets including Brazil, Russia, India and China. Wed, 04 Feb 2009 00:00:00 +0100